Boston, MA 09/06/2013 (wallstreetpr) – There was a great deal of bearish sentiment around Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) even towards the end of August, by many prominent hedge funds.
Some money managers decided to sell their positions completely as the company heads into the second quarter. Over the past 180 days ACHN has seen no unique-insiders purchasing and no insider sales.
Latest trading session
In Thursday’s trading session, ACHN stock rose by 5.41%. The opening price of the shares was $6.69 which touched an intraday high of $7.04 and closed at $7.02. The average volume of shares traded over 30 days was 0.821 million. The company has a market cap of 678.43 million
About the company
Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) is essentially a bio-pharma company. It focused on discovering, developing and commercializing treatments that are used in various infectious diseases. It is involved in developing anti-virals that are used to treat chronic hepatitis C infection. It is also involved in developing anti-bacterials that are used to treat different resistant bacterial infections. The company focuses on developing 4 main drug candidates. All these drug candidates are used for treating HCV.
Other product candidates
Apart from the primary drug candidates, the company has also established a pipeline of some other product candidates. It is now on the lookout for appropriate collaborative partners for these treatments. The company does not have any resources for ACH-2881 and ACH-702 that are for the drug-resistant bacterial infections and elvucitabine that is used for treating HIV infection. The company competes with Merck, Roche, Abbott, Vertex, Astra-Zeneca, Bristol-Meyers Squibb. Companies such as GlaxoSmithKline, Gilead, Johnson&Johnson, Human Genome Sciences, Pfizer, Novartis and Valeant are also amongst its rivals. It is also in competition with companies such as Enanta, Celgene, Idenix , Medivir, Boehringer Ingelheim and Presidio.
